Phatlhane DV, Zemlin AE

Idioma: Ingles.
Referencias bibliográficas: 15
Paginas: 924-928
Archivo PDF: 134.09 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Seidel D, Alaupovic P, Furman RH. A lipoprotein characterizing obstructive jaundice. I. Method for quantitative separation and identification of lipoproteins in jaundiced subjects. J Clin Invest 1969; 48: 1211-23.

2. Ross A, Murphy GM, Wilkinson PA, Mills GL, Sherlock S. Occurrence of an abnormal lipoprotein in patients with liver disease. Gut 1970; 11: 1035-7.

3. Seidel D, Buff HU, Fauser U, Bleyl U. On the metabolism of lipoprotein-X (LP-X). Clin Chim Acta 1976; 66: 195-207.

4. Bhatnagar D, Soran H, Durrington PN. Hypercholesterolaemia and its management. BMJ 2008; 337: 503-8.

5. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478-90.

6. Seidel D. Lipoproteins in liver disease. J Clin Chem Clin Biochem 1987; 25: 541-51.

7. Turchin A, Wiebe DA, Seely EW, Graham T, Longo W, Soiffer R. Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver. Bone Marrow Transplant 2005; 35: 85-9.

8. Zidan H, Lo S, Wiebe D, Talano J, Alemzadeh R. Severe hypercholesterolemia mediated by lipoprotein X in a pediatric patient with chronic graft-versus-host disease of the liver. Pediatr Blood Cancer 2008; 50: 1280-1.

9. Yon JL, Anuras S, Wu K, Forker EL. Granulomatous hepatitis, increased platelet aggregation, and hypercholesterolaemia. Ann Intern Med 1976; 84(2): 148-50.

10. Walli AK, Seidel D. Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein- X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat. J Clin Invest 1984; 74: 867-79.

11. Le Riche M, Burgess LJ, Marais AD. Pseudohyponatraemia in a patient with obstructive jaundice. Clin Chim Acta 2006; 366: 357-60.

12. Sivakumar T, Chaidarun S, Lee HK, Cervinski M, Comi R. Multiple lipoprotein and electrolyte laboratory artifacts caused by lipoprotein X in obstructive biliary cholestasis secondary to pancreatic cancer. J Clin Lipidol 2011; 5: 324-8.

13. Fei H, Maeda S, Kirii H, Fujigaki S, Maekawa N, Fujii H, Wada H, et al. Evaluation of two different homogeneous assays for LDL-cholesterol in lipoprotein-X-positive serum. Clin Chem 2000; 46: 1351-6.

14. Chang P-Y, Lu S-C, Su T-C, Chou S-F, Huang W-H, Morrisett JD, Chen C-H, et al. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res 2004; 45: 2116-22.

15. Crook MA. Lipoprotein X: clinical implications. Ann Clin Biochem 2013; 50: 93-4.